EUVIMEDEUVIMED entdecken
Crossref

Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans

Shuvechha Chakraborty iD, Ameya Pawaskar, Siddhanath Metkari, Taruna Madan, Susan Idicula-Thomas iD

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Shuvechha Chakraborty und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Informatics Centre, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Candida albicans, Antifungal Agents, Fluconazole, Azepines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India, Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Emergence of life‐threatening fungal infections like systemic candidiasis concurrently with bacterial infections and limitations of current antifungal therapies warrant the discovery of novel inhibitors. We identified besifloxacin (BS), an FDA‐approved antibacterial, as a potent antifungal inhibitor. A combination of besifloxacin with fluconazole showed a positive synergy (δ = 29.58) resulting in 80% inhibition of microbial growth. BS was able to reduce the MIC of FLC from 2 mg/L to 0.5 mg/L when used in combination. Additionally, in murine systemic Candida infection, BS reduced fungal load by 83% in mice kidneys at a dose of 100 mg/kg/day. The findings demonstrated the antifungal potential of BS, proposing its use in combination therapy with fluconazole to combat resistance through alternative mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Candida albicansAntifungal AgentsFluconazoleAzepinesFluoroquinolonesAnimalsMicrobial Sensitivity TestsMiceCandidiasisDrug RepositioningDrug Synergism

Stichwörter der Autor:innen

besifloxacindrug combinationdrug repurposingsystemic candidiasis

Substanzen

Antifungal AgentsFluconazolebesifloxacinAzepinesFluoroquinolones

Autor:innen und Institutionen

  • Biomedical Informatics Centre, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, Maharashtra, India.
  • Experimental Animal Facility, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, Maharashtra, India.
  • Indian Council of Medical Research, New Delhi, India.

ORCID-Profile: Shuvechha Chakraborty, Susan Idicula-Thomas

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India
  • Science and Engineering Research Board

Zitieren

APA

Chakraborty, S., Pawaskar, A., Metkari, S., Madan, T., & Idicula-Thomas, S. (2025). Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70138

Vancouver

Chakraborty S, Pawaskar A, Metkari S, Madan T, Idicula-Thomas S. Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70138

BibTeX
@article{Chakraborty2025,
  author = {Chakraborty, Shuvechha and Pawaskar, Ameya and Metkari, Siddhanath and Madan, Taruna and Idicula-Thomas, Susan},
  title = {Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70138}
}
Kostenlos starten →